Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with SBRT in Metastatic Anaplastic Thyroid Cancer
NCT03122496Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in anaplastic thyroid cancer (ATC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT03122496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122496.